Drug Trial Radar · NCT04464733
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
Last checked: Nov 19, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Jul 20, 2020
Primary completion
May 30, 2023
Study completion May 30, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950. The study will be conducted in three parts sequentially: Part 1, evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics of single doses and multiple dose of HRS9950 tablet in healthy subjects. Part 1 will consist of 84 healthy subjects, 8 groups.There will be 14 subjects in 0.75mg dose group,10 subjects in each other dose group . Part 2, evaluate food effect of HRS9950 in healthy subjects. Part 2 will consist of 14 healthy subjects, 1 group (one of groups in Part 1). Part 3, evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics of multiple doses of HRS9950 tablet in naive and treatment-experienced chronic hepatitis B (CHB) patients. Part 3 will consist of 60 CHB patients, 1 group for naive patients and 5 groups for treatment-experienced patients.
Conditions
- Chronic Hepatitis b
Interventions
HRS9950Drug
HRS9950
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of treatment-related adverse events as assessed by CTCAE v5.0Time frame: 8 DAYS for Group A-M; 29 DAYS for Group F; 50 DAYS for Group G-O
- Maximum Plasma Concentration [Cmax]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
- Area under the concentration time curve [AUC]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
- Time to maximum plasma concentration [Tmax]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
- Apparent clearance [CL/F]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
- Half-time [t1/2]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
- Apparent volume of distribution [Vz/F(Vd)]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
- Mean residence time [MRT]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
- The concentration of IL-12p40 in the serumTime frame: 0-48 hours after each dose for Group A-E、G-O
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Youan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.